Back

Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart

17 May 2025 (11:17 - 12:25)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pathophysiology and mechanisms (3) Systolic Ventricular Dysfunction HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Renzo Laborante

South General Hospital, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
The differences between ambulatory and hospitalized heart failure patients with mildly reduced or preserved ejection fractions lessons learned from the HF-POL study
Doctor A. Galas (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Exploring the relationship between cardiopulmonary exercise testing and hemodynamic metrics in advanced heart failure
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Increased pulmonary artery-to-aorta diameter ratio in patients with dyspnea is associated with impaired right ventricular systolic function
Doctor U. Ozpinar (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Factors for heart failure at discharge in takotsubo syndrome
Doctor M. Moura (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Renal dysfunction markers as predictors of ventricular systolic dysfunction six months after STEMI: a prospective analysis
Doctor V. Halatiu (Targu Mures, RO)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pathophysiology and mechanisms (3)

The Event

Event poster

Heart Failure 2025

17 May 2025 11:17 CET
You may be interested in
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?
thumbnail
Congress Presentation
Temporal trends in guideline-directed medical therapy prescription and 30-day readmission after heart failure hospitalization
thumbnail
Congress Presentation
Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources